Abstract Therapeutic attempts to cure Alzheimer's disease (AD) have failed, and new strategies are desperately needed. Motivated by this reality, many laboratories (including our own) have focused on synaptic dysfunction in AD because synaptic changes are highly correlated with the severity of clinical dementia. In particular, memory formation is accompanied by altered synaptic strength, and this phenomenon (and its dysfunction in AD) has been a recent focus for many laboratories. The molecule cyclic adenosine monophosphate response element-binding protein (CREB) is at a central converging point of pathways and mechanisms activated during the processes of synaptic strengthening and memory formation, as CREB phosphorylation leads to transcription of memory-associated genes. Disruption of these mechanisms in AD results in a reduction of CREB activation with accompanying memory impairment. Thus, it is likely that strategies aimed at these mechanisms will lead to future therapies for AD. In this review, we will summarize literature that investigates 5 possible therapeutic pathways for rescuing synaptic dysfunction in AD: 4 enzymatic pathways that lead to CREB phosphorylation (the cyclic adenosine monophosphate cascade, the serine/threonine kinases extracellular regulated kinases 1 and 2, the nitric oxide cascade, and the calpains), as well as histone acetyltransferases and histone deacetylases (2 enzymes that regulate the histone acetylation necessary for gene transcription).
Introduction
For years the debate over the causes of Alzheimer's disease (AD) was dominated by 2 major neuropathologic hallmarks: amyloid plaques, consisting mostly of extracellular deposits of amyloid-beta (Aβ) peptides, a downstream product of the processing of the larger amyloid precursor protein (APP); and neurofibrillary tangles (NFTs), consisting mostly of intraneuronal accumulations of hyperphosphorylated tau protein. However, neither the degree of amyloid plaque nor NFT pathology are as highly correlated with the severity of clinical dementia as synaptic pathology [1] . Both pathogenic Aβ and tau assemblies could, in turn, alter the mechanisms underlying the excitatory response at single synapses producing synaptic dysfunction before synapse loss [2] . Faltering of the synapses at early stages of the disease would underlie subtle amnesic problems in patients with AD. These events would open up a temporal frame during which it might be still possible to intervene therapeutically before any irreversible damage has occurred. Because of this possibility our laboratories and many others have focused their research on the identification of the molecular mechanisms responsible for synaptic dysfunction, in particular mechanisms that impair long-term potentiation (LTP), a type of synaptic strengthening that is likely to underlie learning and memory. A particularly interesting study that developed this idea came from the laboratories of Lloyd Green and Michael Shelanski at Columbia University, where Aβ exposure was found to regulate a group of genes that interfere with the memory and synaptic plasticity molecule cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) in nerve growth factorprimed PC12 cells [3] . CREB is phosphorylated during memory processes by activation of a series of second messenger systems [4] [5] [6] [7] . Its phosphorylation leads to binding to CREB binding protein (CBP), a histone acetyltransferase (HAT) that (similar to other HATs) functions as a coactivator that catalyzes histone acetylation, causing an increase in the transcription of memory-associated genes [8] [9] [10] [11] [12] [13] . This effect on acetylation is counteracted by histone deacetylases (HDACs) which were found to remove an acetyl group from histones, thus reducing gene expression levels. It is therefore likely that derangement of the enzymatic pathways leading to CREB phosphorylation, as well as the transcription machinery interacting with CREB during memory formation, play a key role in synaptic dysfunction and memory loss in AD. Most importantly, targeting the enzymatic pathways and the transcription machinery leading to memory formation may be a useful strategy for treating AD. Here we will summarize the literature supporting the idea of targeting 4 enzymatic pathways leading to CREB phosphorylation, including the cAMP/protein kinase A (PKA)/CREB cascade, the serine/threonine kinases extracellular regulated kinase (ERK) 1 and ERK 2 (ERK1/2), the nitric oxide (NO) cascade, and the calcium-activated neutral cysteine proteases (calpains), as well as HATs and HDACs for a therapy against AD.
cAMP/PKA/CREB Cascade PKA is one of the canonical kinases involved in synaptic plasticity. Discovered over 40 years ago [14] , PKA consists of 2 catalytic components and 2 regulatory components. Various extracellular signals (e.g., synaptic stimulation) induce adenylyl cyclase to produce cAMP, which then binds to the regulatory elements of PKA (PKA-R) resulting in dissociation of PKA-R from the PKA catalytic components. This liberates the PKA catalytic components, which can then phosphorylate (and thus activate) CREB (see [4] for a recent review) (Fig. 1) . There is extensive literature examining PKA dysfunction in animal models of AD, which may be induced through Aβ-mediated oxidative stress [15] , as well as through Aβ-independent mechanisms, such as direct inhibition of the PKA pathway by β-secretase (BACE)1 [16] . Moreover, the antiamnestic effects of both caffeine and environmental enrichment in animal models of AD have been linked to promotion of PKA activity [17, 18] . As an aside, our group has shown that at low physiologic (picomolar) levels, Aβ42 promotes memory formation [19] (with its depletion reducing learning and memory [20] ), and this effect has also been linked to enhancement of the PKA pathway [21] . Finally, our group has shown that pathologic (nanomolar) concentrations of Aβ42 cause a rapid and sustained decrease in PKA activity and inhibition of CREB phosphorylation in hippocampal neuronal cultures in response to glutamate stimulation [3] .
Given the importance of cAMP [as well as cyclic guanosine monophosphate (cGMP)-see below] in the central nervous system, many neuroscientists have become interested in the regulation of cAMP and cGMP. Both cyclic nucleotides are primarily regulated by a family of enzymes called phosphodiesterases (PDEs). PDEs hydrolyze cAMP and cGMP into 5'AMP and 5'GMP, respectively [22] . In particular, PDE4 has been shown to be a major regulator of cAMP [23, 24] . Thus, PDE4 inhibition has been proposed as a therapeutic strategy that can lead to cAMP elevation and increased CREB phosphorylation. Rolipram is a prominent PDE4 inhibitor that has been tested in multiple animal models of AD for this reason [25] . For example, the APP/PS1 mouse model of AD displays impaired synaptic plasticity and memory as early as 3-4 months of age [26] , and our group has found that rolipram rescues LTP, contextual fear conditioning, and spatial working memory in these mice [27] . In this same study, it was shown that improvements in synaptic plasticity and memory persisted for several months after the last dose of rolipram, and this was accompanied by a reversal of the observed decrease in CREB phosphorylation in these mice. A separate study by Cheng et al. [28] found that rolipram treatment reversed the memory deficits seen in rats treated with Aβ1-40. In this study, rolipram also reversed the memory deficits caused by Aβ25-35 (the core fragment of Aβ1-40). Rescue of memory impairment in this animal model was also accompanied by an elevation of phosphorylated CREB. Finally, a third study has examined the effects of PDE4 micro-RNA knockdown in an additional rodent model of AD [29] . In this study, PDE4 knockdown in mice reversed memory deficits caused by hippocampal injection of Aβ1-42. Consistent with the Of note, Uch-L1 activates proteasomal (Pr) degradation of the PKA regulatory subunit, which also promotes CREB phosphorylation through PKA activation. CRE = cAMP response element; CBP = CREB binding protein; p = phospho group previous 2 studies, this improvement in memory was accompanied by an increase in phosphorylated CREB. The consistency of the results across all of these studies supports the use PDE4 inhibition as a treatment of memory dysfunction in AD. As an aside, some have questioned the use of rolipram as an antiamnestic in humans owing to its side effect of severe emesis [30] . In response, newer PDE4 inhibitors have been developed that improve memory without the side effects of rolipram [31] , and which are still effective months after chronic treatment [32] , similarly to rolipram.
All these data lead to the obvious question: Is there impaired PKA activity in the brains of patients with AD? Although this question has not been answered directly, there is circumstantial evidence to support this idea. The brains of patients with AD show an accumulation of ubiquitinated proteins [33] , suggesting inhibition of the protein degradation machinery. Could there be impaired degradation of PKA-R in AD? If this were to occur, it would result in increased binding of PKA-R to the PKA catalytic domain, which would lead to increased inhibition of PKA. Uch-L1, a neuron-and testisspecific enzyme, is associated with protein ubiquitination and long-term facilitation in Aplysia [34, 35] (Fig. 1 ). In addition, Uch-L1 is downregulated in AD brains [36] . There may also be a loss of soluble Uch-L1 in AD brains; NFTs stain for Uch-L1, and levels of soluble Uch-L1 are inversely proportional to tangle burden [36] . This circumstantial evidence has generated interest in studying the mechanism of how decreased Uch-L1 levels may contribute to synaptic dysfunction in AD. The hypothesis is that Uch-L1 normally participates in the degradation of the PKA-R protein, which then allows the PKA catalytic domain to phosphorylate (i.e., activate) CREB. Therefore, when Uch-L1 activity is impaired, PKA-R is not degraded as quickly, the PKA catalytic domain is sequestered, and CREB phosphorylation is impaired.
Our group has investigated the above hypothesis [37] , and we have shown that 1) Uch-L1 protein levels are reduced in the hippocampus of APP/PS1 mice; 2) inhibiting Uch-L1 activity leads to an impairment of hippocampal LTP; and 3) supplementing Uch-L1 protein restores LTP and associative memory in APP/PS1 mice and blocks the Aβ-induced reduction in PKA activity [37] . Additional work has also shown that Uch-L1 treatment can restore spine density in mouse models of AD, and this effect is seen even in elderly mice [38] . Thus, upregulating Uch-L1 activity may be a therapeutic strategy for rescuing synaptic function in AD [39] . As an aside, Uch-L1 has also been shown to be associated with Parkinson's disease. Liu et al. [40] have shown that farnesylation promotes the association of Uch-L1 with cellular membranes, and that this correlates with α-synuclein pathology. The mechanism for this association is unclear, but may relate to loss of functional (soluble) Uch-L1 from the cytoplasm. In any case, farnesyltransferase inhibition reduces α-synuclein levels and improves cell survival in cultures, suggesting that Uch-L1 may also be a therapeutic target for Parkinson's disease.
The ERK1/2 Mitogen-Activated Protein Kinase Pathway
Signaling cascades involving ERK1/2 constitute another pathway that leads to CREB phosphorylation [41] . ERK1/2 are components of 1 of 4 related, but distinct, mitogen-activated protein kinase (MAPK) pathways that also include the c-Jun N-terminal kinase/stress-activated protein kinase [42, 43] , the p38MAPK [44] , and ERK5/big MAP kinase 1 [45] pathways. The canonical ERK signaling pathway consists of a molecular cascade wherein receptor tyrosine kinase activation leads to activation of the guanosine-5'-triphosphatase-activating protein, son of sevenless (SOS), via the adaptor proteins Shc and Grb2 (Fig. 2) . SOS then activates the small guanosine triphosphate-binding protein, Ras, that initiates a 3-member kinase cascade that is the hallmark of MAPK pathways. In the case of ERK, this cascade consists of Raf, mitogen/ extracellular signal-regulated kinase and ERK1/2 [46] . CREB phosphorylation occurs when ERK translocates to the nucleus to phosphorylate CREB kinases. In the case of neurotrophininduced CREB phosphorylation, Msk1 appears to be the critical kinase mediating CREB phosphorylation [47] . Support for the notion that ERK-induced CREB phosphorylation may be beneficial for AD-related impairments comes, in part, from studies of brain-derived neurotrophic factor (BDNF) signaling. BDNF induces CREB phosphorylation by binding to its cell surface receptor, TrkB, and activating the ERK signaling cascade. BDNF has been found to enhance synaptic plasticity and promote cell survival in model systems [48, 49] , both of which are potentially beneficial for AD. Conversely, reduced levels of BDNF in patients with AD or mild cognitive impairment may contribute to cognitive impairments and disease progression in these individuals [50] [51] [52] [53] . Application of sublethal concentrations of Aβ to neurons in culture has also been reported to interfere with BDNF-induced activation of ERK and CREB phosphorylation [54] .
Despite data suggesting a beneficial role for BDNFinduced ERK signaling, evidence suggests that ERK signaling plays a more complex role in AD. ERK can be activated by multiple mechanisms and, in turn, can act on multiple targets. In some cases data suggest that the effect of ERK signaling on AD is likely to be beneficial, and in others that it is likely to be detrimental. Elevated levels of ERK have been reported in the cerebrospinal fluid of patients with AD [55] , and increased levels of activated ERK have been found in postmortem AD brains [55] [56] [57] . A similar increase in activated ERK has also been found in the brains of mice that overexpress a mutant form of APP [58] . However, given that ERK is required for normal learning and memory and normal synaptic plasticity [59, 60] , the extent to which these increases represent contributory or compensatory mechanisms for AD-related impairments remains unclear.
Aβ-induced receptor activation is thought to be one of the mechanisms leading to increased ERK activation in AD brains. The ERK pathway is activated by a number of receptors that bind Aβ, including the ionotropic and metabotropic glutamate receptors N-methyl-D-aspartate and mGluR5 [61] [62] [63] [64] [65] , the receptor for advanced glycation end products [66, 67] , the p75 neurotrophin receptor, integrins, and a number of microglial receptors (reviewed in [68] ). Aβ also interacts with alpha7 nicotinic receptors, which are required for Aβ-induced ERK and CREB phosphorylation [58] . Finally, APP itself may activate the ERK pathway via interactions between its cytoplasmic domain and the adaptor proteins Grb2 and ShcA [69] . To the extent that ERK signaling mediates any of the toxic actions of Aβ, this pathway may also contribute to AD. Data consistent with hypothesis come from studies using a synthetic p75 neurotrophin receptor ligand, LM11A-31, which was found to inhibit Aβ-induced synaptic dysfunction and memory loss [70] .
Excitotoxicity and dysregulated calcium homeostasis are thought to occur in neurons affected by AD, and the resulting increases in intracellular calcium can also activate the ERK pathway via a number of molecular mechanisms [71, 72] . In addition oxidative stress is thought to play a significant role in AD pathogenesis and can similarly lead to ERK activation via multiple pathways. Given that ERK activation of CREB induces the expression of a number of antioxidant genes, activation of this pathway may represent an adaptive mechanism to reduce oxidative damage (reviewed in [73] ). This contention is supported by the observation that molecularly interfering with CREB increases seizure-induced cell death and production of reactive oxygen species, and blocked the neuroprotective effect of BDNF [74] .
In addition to CREB, the ERK pathway regulates 2 proteins that are critically involved in AD: the microtubuleassociated protein, tau [75] [76] [77] [78] [79] [80] [81] , and APP. In the case of tau, hyperphosphorylation is thought to play a key role in AD pathogenesis [82] , and pharmacological inhibition of ERK1 or molecular inhibition of its upstream activator, Ras, has been found to prevent Aβ-induced increases in tau phosphorylation [83, 84] . In contrast, ERK pathway regulation of APP processing may protect against AD. ERK activation increases soluble APPα production, a downstream product of APP processing, and reduces production of the toxic Aβ peptide [85, 86] . ERK inhibition also blocks the increase in Aβ production caused by exposure to high concentrations of Nmethyl-D-aspartate in mice. These actions are owing, at least in part, to ERK-dependent regulation of the activity and expression of α-and γ-secretases, the 2 enzymes responsible for APP processing [87] [88] [89] [90] [91] .
Clearly, the ERK pathway and ERK-mediated CREB phosphorylation play a critical role in AD. While significant progress has been made in unraveling its complex molecular interactions, we still lack a complete understanding of all the ways in which this pathway affects the development and progression of the disease. This understanding will be critical for the future development of AD therapeutic strategies that target this pathway
The NO Cascade NO is a gaseous molecule released from the conversion of the amino acid L-arginine to L-citrulline by the enzyme NO synthase (NOS). In particular, the neural NO synthase, activated in response to Ca 2+ /calmodulin, is widely expressed in the brain, especially in the cortex and hippocampus [92] , where it has been implicated in pre-and postsynaptic mechanisms underlying synaptic plasticity (for a review see [93] ). NO acts on soluble receptor guanylate cyclase (sGC) stimulating the production of the second messenger cGMP, which, in turn, is able to activate protein kinase G (PKG), the activity of which maintains CREB phosphorylation at Ser133 [94, 95] (Fig. 3) . NO also mediates CREB-DNA binding via a Ser133-independent mechanism by the S-nitrosylation of nuclear proteins associated with CREB target genes [96] . Various studies have suggested that NO/cGMP/PKG and cAMP/PKA cooperate to ensure different phases of LTP and to underpin memory acquisition and consolidation via CREB phosphorylation [94, [97] [98] [99] [100] . CREB phosphorylation is now recognized as a crucial event that regulates transcription during synaptic plasticity [101] [102] [103] , leading to protein synthesis and the generation of new dendritic spines to ensure longterm morphological changes associated with late LTP [104] .
The NO/cGMP/PKG/CREB system is disrupted during Aβ-induced suppression of synaptic plasticity. This occurs through Aβ-mediated inhibition of NO-induced CREB phosphorylation [105] [106] [107] [108] [109] [110] [111] , and toxicity may be exacerbated because the NO/cGMP signaling pathway exerts a protective role against Aβ-mediated neurotoxicity [112] [113] [114] . We have previously demonstrated that the use of NO donors or cGMP agonists was able to rescue the Aβ-induced impairment of LTP and CREB phosphorylation, whereas sGC or PKG inhibition suppresses this neuroprotective effect [110] . Moreover, sGC activity and cGMP production are blocked by Aβ in brain astroglial cells and tetanized hippocampal slices [109, 110] , as well as in temporal cortex of patients with AD [115] .
As PKG phosphorylates (and activates) CREB [94] , and the therapeutic effect of cGMP analogs in the setting of elevated Aβ requires PKG function [110] , the beneficial effects of cGMP analogs on synaptic plasticity and memory in the setting of elevated Aβ might involve CREB. Several lines of evidence are consistent with this hypothesis: 1) the inhibition of 1 of the components of the NO/cGMP/PKG pathway suppresses CREB phosphorylation [94, 116, 117] ; 2) the increase of phospho-CREB during synaptic plasticity is blocked by Aβ in cultured cortical neurons [118] , in cultured hippocampal neurons [3] , and in hippocampal tetanized slices treated with Aβ [110] ; and 3) stimulation of the NO/sGC/ cGMP pathway restores levels of phospho-CREB [112, 113] . Because of these findings, and considering that the NO cascade is downregulated during aging and in neurodegenerative disorders [112, 113, [119] [120] [121] [122] , an increasing number of studies have focused on therapeutic strategies aimed to regulate this signaling pathway.
Other than classical nitrates or hybrid nitrates, NO donor nonsteroidal anti-inflammatory drugs [123] [124] [125] [126] [127] , an additional therapeutic approach is to block the degradation of cGMP by using PDE5 inhibitors (PDE5-Is). Over the past few years, our group and others have demonstrated that treatment with PDE5-Is rescues synaptic and memory deficits in the APP/ PS1 mouse model of AD, restoring phospho-CREB levels and decreasing Aβ load [112, 128] . The PDE5-I sildenafil also exerts the same beneficial effect in a physiological mouse model of aging [113] , where it also inhibits apoptosis and increases antiapoptotic molecules Bcl2 and BDNF [129] .
The use of PDE5-Is to rescue cognitive function in AD is intriguing, especially given our understanding of the relatively benign side effect profile from long-term use of PDE5-Is to treat male erectile dysfunction. Indeed, similarly to PDE4 inhibition [3] , our data suggest that a temporary PDE5-Iinduced upregulation of CREB phosphorylation produces a prolonged beneficial effect that extends beyond the duration of the drug administration. Thus, acting on the NO/cGMP/ PKG/CREB pathway may not only counteract the effects of high levels of Aβ, but it could also delay the progression of the disease and prevent or reduce cognitive impairment.
Calpains
Calpains are a family of at least 15 proteases diffused throughout the body with different specificities [130, 131] . Protein cleavage is an activity typically directed at the catabolism of peptides and protein. However, limited nondigestive proteolysis is also a particular form of post-translational modification changing both the activity and possibly the localization of cell proteins [132] . Calpains are localized in the central nervous system with 2 isoforms (calpain I and II) that are under intense functional characterization [133] . Typically, calcium concentration-dependent driven autoproteolysis activates calpains [134] , and this phenomenon is dramatically increased in neurodegenerative disease [135, 136] . Characteristically, calpains clip a small portion of a protein (proactivation cleavage) determining the functional activation of the cleaved protein. A straightforward example of this activity occurs with CaMKIIα, protein kinase C, and PP3α/calcineurin, all proteins involved in synaptic plasticity and memory mechanisms [137] [138] [139] [140] , which are activated by calpains by cleavage of their respective inhibitory domain [141] [142] [143] (Fig. 4) . Calpains hit many targets, including proteins and enzymes involved in mechanisms of synaptic plasticity, learning and memory, transcription factors such as CREB, and translational factors like cytoplasmic polyadenylation element-binding protein 3, a sequence-specific RNA-binding protein that represses translation of its target mRNAs in neurons. Through the regulation of CREB and cytoplasmic polyadenylation element-binding protein 3 [144, 145] , calpains indirectly modulate gene transcription or transduction. CREB is composed of a C-terminal promoter-binding domain and an N-terminal transcription regulation domain in which PKA can phosphorylate the amino acid serine in position 133, a step required for the regulation of gene expression along with the dimerization and the inclusion in a transcription complex that includes CBP [146] . Calpain-cleaved CREB preserves serine 133 phosphorylation and recognizes cAMP response element sequences on DNA while losing its major influence in activating the transcription process [144, 145] . However, when calpains are overactivated in response to overshoots of calcium influx, such as in neurodegenerative disease like AD or ischemic insults [136, [147] [148] [149] [150] [151] [152] [153] , phosphorylated CREB levels decrease and the phenomenon is accompanied by a decline of both synaptic plasticity and memory [154] .
The mechanisms behind the modulatory activity of calpains on plasticity and memory are not well characterized yet and several hypotheses have been proposed over time to rationalize the proteolysis of key targets such as synaptic receptors or kinase activity (see [133] for a recent review). Di Rosa et al. [155] have shown that the cystein protease inhibitor leupeptine decreases the frequency of spontaneous release of neurotransmitter, suggesting a role of calpains in neurotransmitter release. Moreover, calpastatin, the endogenous inhibitor of the calpain system, unravels a function of calpains in learning and memory as rats deficient in calpastatin show enhanced learning and memory [156] . An additional activity is the tight regulation of PKA and, again, CREB activity. Indeed, the decline of PKA levels by calpain activation or overactivation generates, in turn, a correspondent increase in CREB truncation, and decrease in CREB phosphorylation and activation [145, 157] , leading to decreased plasticity and poor cognitive performance.
The mechanisms underlying synaptic plasticity are severely impaired in AD from the early stages of the disease [1, 158, 159] . One of the culprits of AD is the overactivation of calpains because of calcium homeostasis changes (see [160] for a critical review). Enhanced calpain activation produces augmented APP processing via BACE activation and augmented Aβ deposit [161] , increases tau-mediated neuropathology [162] , and disrupts the functionality of kinases such as CDK5 by pushing the cleavage of the CDK5 activator p35 [163] , but also induces microgliosis, somatodendritic dystrophy, and increased mortality while the endogenous calpain inhibitor calpastatin is knocked down in animal models of AD [164] . This evidence supports the possible use of calpain inhibitors as a therapeutic treatment in AD [153] [154] [155] . The field of medicinal chemistry is currently engaged in producing a variety of molecules as possible calpain inhibitor candidates [165, 166] . Most of them are chemically-related to a natural compound called E-64 that irreversibly but not selectively inhibits calpains [167] [168] [169] . E-64 exhibits excellent activity in transgenic models of AD in vitro and in vivo [154, 170] , rescuing the AD phenotype in terms of synaptic plasticity and memory. However, the nonselective nature of E-64 seems unfavorable for clinical use, so an interesting development for this class of compounds against AD is the development of a novel calpain I-selective peptidomimetic, based on E-64 as a lead compound. Schiefer et al. [171] designed a new series of derivatives with favorable pharmacodynamic characteristics that maintain drug potency while increasing calpain I selectivity and druggability [171] . BDA-410, an orally active synthetic Leu-Leu peptidomimetic rescues synaptic plasticity defects and memory impairment in an APP/PS1 AD mouse model but does not alter Aβ productions and increases CREB phosphorylation [154] . This fact confirms the efficiency of the epoxide derivatives toward AD. Other inhibitors such as AK 295 or MDL 28170 have never been thoroughly characterized as AD therapeutics, although MDL 28170 is known to inhibit γ-secretase, responsible for the cleavage of APP to produce Aβ [172, 173] . Another orally active and very promising compound is A-705253, a benzoylalanine-derived ketoamide that is under intense scrutiny and characterization. A-705253 proved to be active in the prevention of both tau phosphorylation and cleavage [174, 175] , and it is active in the 3xTgAD mouse model rescuing memory defects, reducing levels of BACE enzyme and Aβ deposits, decreasing overall neuroinflammation [174, 176] . Taken together, these data suggest that calpain inhibition might be an efficient and reliable target for AD therapy.
HDACs and HATs
During memory formation CREB binds to CBP, an enzyme with HAT activity, representing one of the epigenetic processes leading to chromatin remodeling and DNA transcription (Fig. 5) . CBP belongs to 1 of the 5 major HAT groups: CBP/ p300; Gcn5-related N-acetyltransferases (including Gcn5 and p300/CBP-associated factor); MYST (MOZ, Ybf2, Sas2, and Tip60); nuclear receptor-associated HATs; and transcription factor-related HATs [177] . On the other side, HDACs function to remove acetyl groups from histone lysines, repressing gene transcription. The HDAC family comprises 18 members, grouped into 4 classes: HDAC I (HDACs 1-3 and HDAC8); HDAC II, which is divided into IIA (HDAC4, HDAC5, HDAC7, and HDAC9) and IIB (HDAC6 and HDAC10); HDAC III (Sirt 1-7); and HDAC IV (HDAC11) [177, 178] . In the last decade the correlation between learning and memory and histone acetylation has been deeply explored [8] [9] [10] [11] [12] . Studies have shown that acetylation levels of histone 3 and histone 4 are increased during spatial and associative learning in the hippocampus and cortex [8, 179, 180] . The increase of histone acetylation levels leads to transcription of memorypromoting genes, such as cFos, BDNF-IV, EGR1, and Nr4a1 and Nr4a2 [181] [182] [183] [184] (Fig. 5) . Regulation of gene transcription via modification of chromatin structure has been of particular interest for the treatment of various diseases. Recently, the alteration of HDAC and HAT activity by using small molecules, that is HDAC inhibitors and HAT activators, has been considered as a possible therapeutic avenue for the treatment of AD [185, 186] .
Alteration of histone acetylation levels are related to the processes of memory consolidation [8] [9] [10] [11] [12] [13] . A number of studies have focused on the role of HDAC inhibitors (HDACi) in enhancing LTP and long-term memory (LTM) in rodents and mutant mouse models. Synaptic plasticity was increased in hippocampus slices, from APP/PS1 mice, perfused with trichostatin A (TSA), a well-known class I/II HDACi [186] . Also, in a contextual fear conditioning assessment, TSA was shown to rescue spatial memory deficits in APP/PS1 mice [186] . Both TSA and sodium butyrate (class I/II HDACi) were able to ameliorate LTP in hippocampus slices from Sprague-Dawley rats [8] . In addition, sodium butyrate enhanced freezing in Sprague-Dawley rats and in CK-p25 mutant mice [8, 179] , and improved the LTM of cbp mutant mice in a novel object recognition task [187] . Another study showed that in a visualpaired comparison task CBP mutant mice (in which HAT activity is eliminated) displayed impaired LTM, which was rescued after treatment with TSA [11] . Mutant mice that express a truncated form of CBP (cbp +/-) showed impaired LTM in novel object recognition task and reduced synaptic plasticity than wild-type mice. Treatment with suberoylanilide hydroxamic acid (HDAC I/HDAC II inhibitor) rescued memory deficits and increased LTP in slices of hippocampus [9] . Consistent with previous results, treatment with the HDACi sodium 4-phenylbutyrate restored synaptic plasticity and memory impairment in Tg2576 mice [188] . To define the molecular pathways underlying histone acetylation modifications during memory consolidation, Vecsey et al. [184] demonstrated that the interaction between CREB and the transcriptional coactivator CBP was required to enhance the LTP after treatment with HDACi. They found that TSA was not able to enhance LTP or freezing levels in CREBαΔ and cbp KIX/ KIX mutant mice in which the formation of the CREB-CBP complex was disrupted. Moreover, TSA enhanced the expression of Nr4a1 and Nr4a2 after fear conditioning in wild-type mice but not in CREBαΔ mutant mice, suggesting that Nr4a1 and Nr4a2 expression was CREB-CBP dependent after contextual fear conditioning. To investigate whether the CBP homolog, the transcriptional coactivator p300, was also involved in LTM formation, Oliveira et al. [189] tested a transgenic mice model, p300Δ1, in which the HAT domain of the p300 protein was truncated. These transgenic mice showed impairment in recognition and contextual fear memory, demonstrating that p300 was required in the gene transcription induced by learning processes. It also been reported that loss of p300/CBP-associated factor leads to LTM deficits in 6-and 12-month-old mice [190] . Thus, HAT activity seems to be necessary for establishing LTM formation and consolidation owing to its involvement in learningdependent chromatin remodeling. Lately, an alternative approach to modulating the acetylation levels of histones has been represented by employing small HAT activator molecules for treating neurodegenerative disorders [177] . A few HAT activators have been discovered and 2 of them used for studying brain functions in vivo [191, 192] . Wei et al. [191] evaluated the effects of a PCAF activator, SPV106, on fear conditioning and extinction. As a result, PCAF activity was found to facilitate the formation of fear extinction memory without affecting fear acquisition. Instead, Chatterjee et al. [192] reported the beneficial implications of TTK21, a p300/CBP activator, on LTM by testing spatial learning and memory in the Morris water maze task. Overall, molecules able to modulate the levels of histone acetylation, such as HDACi and HAT activators, represent a promising approach for treating cognitive aspects of neurodegenerative disorders. Despite the growing interest in investigating how chromatin manipulation lies behind the processes of learning and memory, further effort is still required in terms of drug design, specificity, and brain targeting.
Conclusions
Over the last 15 years a large amount of work has been performed on CREB and its possible exploitation for a therapy against AD. When our laboratories and others started this research, the use of drugs enhancing CREB activation was envisioned as a strategy that could work at the downstream level of Aβ and was therefore probably devoid of any putative side effect due the physiological function/s of APP and its downstream products, as well as the secretases responsible for APP processing [19, 20, [193] [194] [195] [196] [197] . Nevertheless, should drugs acting onto amyloid deposition or even drugs interfering with NFT formation provide a safe and effective approach against AD, one can envision a scenario in which agents enhancing CREB activation are given in a combination therapy with anti-Aβ and/or anti-tau therapies.
Given all of the success in rescuing memory through CREB function in AD, an important question should be asked: Is there any downside to chronically increasing CREB phosphorylation? It is also important to remember that CREB is involved in a wide range of physiological processes in a range of tissues [198] , and that CREB is also an oncogene [199] . Moreover, one can predict that our knowledge of the regulation of CREB will evolve with time as new studies unravel novel aspects of the complex mechanisms regulating its activation and elucidate its role in learning and memory. These caveats have led some to question whether a CREB-centric approach is a viable therapeutic strategy at all [198] . These are important issues.
However, it is important to realize that we are not advocating for long-term pharmacologic elevation of CREB activity above normal levels, but rather to rescue the impairment in CREB phosphorylation seen in AD. Thus, although the ultimate test will be clinical trial data, there is reason to suspect that a CREBcentric approach will be successful.
